NON-INSULIN DRUGS IN DIABETES MELLITUS TYPE 1 (METFORMINE, IDPP-4, PRAMLINTIDA, AGLP-1, ISGLT-2)
There are approximately 25 million patients with type 1 diabetes mellitus (DM1) in the world, a figure that would triple in 2050. Although the optimum is to reach A1c levels <7% to avoid and / or slow down the onset / evolution of chronic complications, only 30% of patients achieve this. Furtherm...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Sello Editorial Lugones
2020-07-01
|
| Series: | Revista de la Sociedad Argentina de Diabetes |
| Subjects: | |
| Online Access: | https://www.revistasad.com/index.php/diabetes/article/view/230 |
| Summary: | There are approximately 25 million patients with type 1 diabetes mellitus (DM1) in the world, a figure that would triple in 2050. Although the optimum is to reach A1c levels <7% to avoid and / or slow down the onset / evolution of chronic complications, only 30% of patients achieve this. Furthermore, carbohydrate (HD) count without adequate general dietary education, associated with intensified insulin therapy (IT), is nowadays linked to a higher incidence of hypoglycemia, obesity and other risk factors such as dyslipidemia (DSL), hypertension (HT), obesity (O) and abdominal obesity (OA) in this population, which generates a very frequent phenotype of patients with DM1 associated with metabolic syndrome (SM). |
|---|---|
| ISSN: | 0325-5247 2346-9420 |